CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 14 enrolled
Drug / intervention
Montelukastdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01754220
NCT01754220Phase 4Completed
CompareCT.gov

The Effects of Alvokast (Montelukast) in Patients With Chronic Cough

Association Asthma, Bulgaria·interventional·Posted Dec 21, 2012·Updated Dec 21, 2012

In Brief

A Phase 4 clinical trial evaluating Montelukast for Coughing. Completed, enrolled 14 participants across 1 site.

Detailed Summary

Montelukast, a leukotriene receptor antagonist, is likely to be effective in the treatment of chronic cough and this could be made objective by measuring cough threshold before and after two weeks of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoughing
CountriesBulgaria
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 21, 2012
Enrollment StartMar 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.5 years ago

Interventions

Montelukastdrug

Montelukast is a leukotriene receptor antagonist